Halobetasol propionate 0.5 MG/ML Topical Foam — RxCUI 2047646
RxNorm drug concept · Semantic clinical drug
RxCUI 2047646
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2047646
Official nameHalobetasol propionate 0.5 MG/ML Topical Foam
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ashalobetasol propionate 0.05 % Topical Foam
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)382 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Halobetasol Topical: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Halobetasol topical is used to treat inflammatory skin conditions — conditions that cause redness, swelling, and itching. The ointment form is used broadly for skin conditions that...
- You should use halobetasol topical for no longer than two consecutive weeks, and no more than 50 grams total per week. It's a very potent steroid, and using it longer or in larger...
- Yes — avoid applying halobetasol to your face, groin, or underarms. These areas have thinner skin and absorb much more of the medication, increasing your risk of side effects. Also...
- Are there places I should not apply this?
🕸️ Concept Web — How Halobetasol propionate 0.5 MG/ML Topical Foam Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Halobetasol propionate 0.5 MG/ML Topical Foam
RxCUI 2047646 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Halobetasol
41208IN -
Halobetasol propionate
45318PIN
-
Halobetasol
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Lexette
2106581BN
-
Lexette
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Halobetasol Topical Foam
2047645SCDF -
Halobetasol propionate Topical Foam
2648945SCDFP -
Halobetasol Topical Product
1158362SCDG -
Halobetasol propionate Topical Product
2659417SCDGP -
Halobetasol Topical Foam [Lexette]
2106583SBDF -
Halobetasol propionate Topical Foam [Lexette]
2656190SBDFP -
Lexette Topical Product
2106584SBDG -
Topical Foam
346285DF - +1 more in this family
-
Halobetasol Topical Foam
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Halobetasol propionate 0.5 MG/ML
977989SCDC -
Halobetasol propionate 0.5 MG/ML Topical Foam [Lexette]
2106585SBD -
Halobetasol propionate 0.5 MG/ML [Lexette]
2106582SBDC
-
Halobetasol propionate 0.5 MG/ML
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Halobetasol propionate 0.5 MG/ML
SCDC · 977989 -
Halobetasol Topical Foam
SCDF · 2047645 -
Halobetasol propionate Topical Foam
SCDFP · 2648945 -
Halobetasol Topical Product
SCDG · 1158362 -
Halobetasol propionate Topical Product
SCDGP · 2659417
Brand-Name Concepts
-
Halobetasol propionate 0.5 MG/ML Topical Foam [Lexette]
SBD · 2106585 -
Halobetasol propionate 0.5 MG/ML [Lexette]
SBDC · 2106582 -
Halobetasol Topical Foam [Lexette]
SBDF · 2106583 -
Halobetasol propionate Topical Foam [Lexette]
SBDFP · 2656190 -
Lexette Topical Product
SBDG · 2106584 -
Lexette
BN · 2106581
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2047646 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51862-0618-50 | 1 CANISTER in 1 CARTON (51862-618-50) / 50 g in 1 CANISTER | LEXETTE | Mayne Pharma | 2025-08-08 |
| 68308-0769-50 | 1 CANISTER in 1 CARTON (68308-769-50) / 50 g in 1 CANISTER | Halobetasol propionate | Mayne Pharma | 2023-12-01 |
Observed labelers:
Mayne Pharma (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.